Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer

Radiation Oncology

Zhuomin Yin¹  Ming Chen²  Huarong Tang³  Hanmei Lou³  Juan Ni³  Qiong Zhou³ 

[1] 0000 0004 1762 8363, grid.452666.5, Department of Radiation Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China;0000 0004 1808 0985, grid.417397.f, Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China;0000 0004 1762 8363, grid.452666.5, Department of Radiation Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China;0000 0004 1808 0985, grid.417397.f, Department of Radiation Oncology (Zhejiang Key Laboratory of Radiation Oncology), Zhejiang Cancer Hospital, No. 1 Banshan East Road, 310022, Hangzhou, China;0000 0004 1808 0985, grid.417397.f, Department of Gynecologic Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China;

关键词: Uterine cervical neoplasms;    Organ metastasis;    Primary tumor treatment;    Definitive;    Radiotherapy;   

DOI  :  10.1186/s13014-019-1297-x

来源: publisher

【 摘 要 】

BackgroundThe clinical efficacy of definitive pelvic radiotherapy for primary tumors in patients with newly diagnosed organ metastatic cervical cancer is unclear. Therefore, we conducted a retrospective study to evaluate the efficacy of definitive pelvic radiotherapy combined with systemic chemotherapy in patients with organ metastatic cervical cancer.MethodsWe retrospectively analysed medical records from patients with newly diagnosed organ metastatic cervical cancer, all treated with chemotherapy at the Zhejiang Cancer Hospital between October 2006 and December 2016. Survival times were compared using the Kaplan-Meier method. The univariate log-rank method and multivariate Cox proportional hazard models were used to identify associated variables with survival.ResultsA total of 48 patients were identified from 11,982 primary cervical cancer patients and divided into two groups according to treatment mode: 36 patients received chemotherapy combined with definitive pelvic radiotherapy (group A), 12 patients underwent chemotherapy with/without palliative pelvic radiotherapy (group B). Median follow-up was 14.4 months (range, 4.6–114.7 months). Median overall survival (OS) for group A and group B was 17.3 and 10 months, respectively. Using the univariate analysis, group A was found to have a better OS than group B (p = 0.002). In multivariate analysis, group A (hazard ratio [HR], 0.32; 95% confidence interval [CI], 0.15–0.67, p = 0.003) was associated with lower risk of death compared with group B. The main reason for treatment failure was found to be due to the progression of distant metastatic lesions in 36 patients (75%) from the whole cohort.ConclusionIn this cohort of organ metastatic cervical cancer patients in good performance status, chemotherapy combined with definitive pelvic radiotherapy was associated with improved survival outcomes when compared with chemotherapy with/without palliative pelvic radiotherapy. Prospective trials evaluating definitive pelvic radiotherapy for newly diagnosed organ metastatic cervical cancer, therefore, are warranted.

【 授权许可】

CC BY